{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:43:56Z","timestamp":1787586236605,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jbo.2025.100738","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T15:10:54Z","timestamp":1767539454000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-6785","authenticated-orcid":false,"given":"Cyrille B.","family":"Confavreux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bosco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Desameric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2025.100738_b0005","doi-asserted-by":"crossref","unstructured":"R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243s 9s.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"10.1016\/j.jbo.2025.100738_b0010","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jbo.2025.100738_b0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","article-title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","volume":"89","author":"Kuchuk","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: A retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.31557\/APJCP.2019.20.1.45","article-title":"Incidence and risk factors for bone metastasis in non-small cell lung cancer","volume":"20","author":"da Silva","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jbo.2025.100738_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2025.100738_b0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie 0601 Team. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0045","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbo.2025.100738_b0050","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jbo.2025.100738_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrclinonc.2011.197","article-title":"Denosumab in patients with cancer-a surgical strike against the osteoclast","volume":"9","author":"Brown","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0060","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S1470-2045(12)70470-9","article-title":"NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours","volume":"13","author":"Jilani","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0065","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"ESMO guidelines committee. Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jbo.2025.100738_b0075","doi-asserted-by":"crossref","unstructured":"P. Tuppin J. Rudant P. Constantinou C. Gastaldi-M\u00e9nager A. Rachas L. de Roquefeuil et al. Value of a national administrative database to guide public decisions: From the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France Rev Epidemiol Sante Publique 65 Suppl 4 2017 S149 S67.","DOI":"10.1016\/j.respe.2017.05.004"},{"issue":"8","key":"10.1016\/j.jbo.2025.100738_b0080","doi-asserted-by":"crossref","first-page":"ziaf081","DOI":"10.1093\/jbmrpl\/ziaf081","article-title":"Epidemiology of bone metastasis in France between 2009 and 2018","volume":"9","author":"Marchal","year":"2025","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jbo.2025.100738_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116243","article-title":"Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe","volume":"154","author":"von Moos","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2025.100738_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069214","article-title":"Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital","volume":"13","author":"Seesaghur","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbo.2025.100738_b0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10198-020-01247-z","article-title":"Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are na\u00efve to bone-targeting agents: A comparative analysis of patients with and without skeletal-related events","volume":"22","author":"Hardtstock","year":"2021","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jbo.2025.100738_b0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1634\/theoncologist.2007-0200","article-title":"Use of intravenous bisphosphonates in older women with breast cancer","volume":"13","author":"Giordano","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2025.100738_b0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2017.03.031","article-title":"Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer-results from the prospective German tumour Registry breast cancer cohort study","volume":"79","author":"Schr\u00f6der","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2025.100738_b0120","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0125","doi-asserted-by":"crossref","unstructured":"S. D'Oronzo R. Coleman J. Brown F. Silvestris Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management J Bone Oncol 15 2018 004 4.","DOI":"10.1016\/j.jbo.2018.10.004"},{"key":"10.1016\/j.jbo.2025.100738_b0130","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jbo.2025.100738_b0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"G\u00fcl","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jbo.2025.100738_b0145","doi-asserted-by":"crossref","DOI":"10.1188\/15.CJON.E108-E114","article-title":"Analysis of denosumab on skeletal-related events in patients with advanced breast cancer","volume":"19","author":"Bink","year":"2015","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.jbo.2025.100738_b0150","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2025.100738_b0155","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.jbo.2025.100738_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ajco.13315","article-title":"Optimizing skeletal-related events prevention in patients with advanced prostate cancer","volume":"16","author":"Leung","year":"2020","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100738_b0165","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2025.100738_b0170","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J. Thorac. Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742500079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742500079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:36:42Z","timestamp":1768999002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213742500079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"alternative-id":["S221213742500079X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100738","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}